Wellington Management Group LLP grew its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 163.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 156,906 shares of the company’s stock after acquiring an additional 97,398 shares during the period. Wellington Management Group LLP owned 0.07% of Relay Therapeutics worth $2,936,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently bought and sold shares of the company. KBC Group NV bought a new position in Relay Therapeutics in the first quarter valued at about $34,000. Allworth Financial LP acquired a new position in shares of Relay Therapeutics in the 2nd quarter valued at $34,000. Smartleaf Asset Management LLC grew its stake in shares of Relay Therapeutics by 288.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock worth $37,000 after purchasing an additional 3,287 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Relay Therapeutics during the fourth quarter worth about $46,000. Finally, Captrust Financial Advisors acquired a new stake in shares of Relay Therapeutics in the 2nd quarter valued at approximately $49,000. Institutional investors and hedge funds own 96.98% of the company’s stock.
Relay Therapeutics Stock Up 1.2%
RLAY opened at $18.89 on Friday. The stock has a market capitalization of $4.14 billion, a price-to-earnings ratio of -12.03 and a beta of 1.69. Relay Therapeutics, Inc. has a twelve month low of $3.88 and a twelve month high of $21.27. The company has a 50-day simple moving average of $19.37 and a 200 day simple moving average of $15.41.
Insider Buying and Selling at Relay Therapeutics
In related news, CFO Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $18.94, for a total value of $335,559.98. Following the transaction, the chief financial officer directly owned 122,851 shares of the company’s stock, valued at $2,326,797.94. This trade represents a 12.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Peter Rahmer sold 4,508 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $20.03, for a total transaction of $90,295.24. Following the transaction, the insider owned 223,657 shares of the company’s stock, valued at approximately $4,479,849.71. This represents a 1.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,488,593 shares of company stock worth $125,133,958 in the last three months. Company insiders own 5.04% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on RLAY. JonesTrading upgraded Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. JPMorgan Chase & Co. lifted their price objective on shares of Relay Therapeutics from $28.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Zacks Research raised Relay Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. UBS Group set a $26.00 price objective on shares of Relay Therapeutics in a research report on Tuesday, May 19th. Finally, Barclays increased their target price on Relay Therapeutics from $27.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.92.
View Our Latest Report on Relay Therapeutics
Relay Therapeutics Company Profile
Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.
The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.
Read More
- Five stocks we like better than Relay Therapeutics
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
